Myc Luciferase Reporter Lentivirus

Catalog #
78628
$835 *
Size: 500 µl x 2
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Myc Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the Myc response element located upstream of the minimal TATA promoter (Figure 1) and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, the Myc signaling pathway in the target cells can be monitored by measuring the luciferase activity.

Figure 1. Schematic of the lenti-vector used to generate the Myc luciferase reporter lentivirus.

Product Info
Storage and Usage
Citations
Supplied As
Two vials (500 µl x 2) of lentivirus at a titer >107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Materials Required But Not Supplied
Name Ordering Information
HCT116 cells ATCC #CCL-247
ICG-001 Selleckchem #S2662
Thaw Medium 7 BPS Bioscience #60185
Assay Medium 7B BPS Bioscience #79718
Polybrene Millipore, #TR-1003-G
96-well tissue culture, clear-bottom, white plate Corning, #3610
One-Step luciferase assay system BPS Bioscience #60690
Luminometer  
Formulation

The lentivirus particles were produced from HEK293T cells. They are supplied in cell culture medium containing 90% DMEM + 10% FBS.

Background

The Myc signaling pathway plays an important role in cell proliferation, differentiation, transformation and apoptosis. c-Myc is a transcription factor that heterodimerizes with Max to regulate Myc signaling pathway-responsive genes. Genetic alterations in MYC have been linked to a number of human cancers, including Burkitt’s lymphoma, cervical, ovarian, breast, lung and pancreatic carcinomas. Thus, Myc is a promising therapeutic target for cancer treatment. Myc can be activated by the Wnt/β-catenin pathway.